UnknownPhase 4NCT02198248
Low-dose Glucocorticoid Vasculitis Induction Study
Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chiba University
- Principal Investigator
- Hiroshi Nakajima, M.D., Ph.DChiba University Hospital
- Intervention
- Rituximab(drug)
- Enrollment
- 140 enrolled
- Eligibility
- 20 years · All sexes
- Timeline
- 2014 – 2021
Study locations (17)
- Asahi General Hospital, Asahi, Chiba, Japan
- Kameda Medical Centre, Kamogawa, Chiba, Japan
- Matsudo City Hospital, Matsudo, Chiba, Japan
- Japanese Red Cross Narita Hospital, Narita, Chiba, Japan
- Shimoshizu Hospital, Yotsukaidō, Chiba, Japan
- Hokkaido University, Sapporo, Hokkaido, Japan
- Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan
- Saitama Medical Center, Kawagoe, Saitama, Japan
- Dokkyo Medical University, Mibu, Tochigi, Japan
- Keio University Hospital, Shinanomachi, Tokyo, Japan
- Teikyo University, tabashi City, Tokyo, Japan
- Akita University, Akita, Japan
- Chiba University Hospital, Chiba, Japan
- Chiba Aoba Municipal Hospital, Chiba, Japan
- Chiba East Hospital, Chiba, Japan
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02198248 on ClinicalTrials.govOther trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07556484Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeMayo Clinic
- RECRUITINGEARLY PHASE1NCT07507201Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNCT07258524PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisUniversity of Edinburgh
- RECRUITINGPHASE1NCT07315087CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT06983821Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)Ottawa Hospital Research Institute
- RECRUITINGPHASE3NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisStaidson (Beijing) Biopharmaceuticals Co., Ltd
- RECRUITINGNCT07151521(68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRuijin Hospital
See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →